Intraocular nanoparticle drug delivery: A pilot study using an aerosol during pars plana vitrectomy

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 11, 2007, Pages 5243-5249

  Zhang, Guifang ^a   Feng, Xiao ^a   Wabner, Kathy ^a   Fandrey, Chris ^b   Naqwi, Amir ^b   Wiedmann, Timothy ^a   Olsen, Timothy W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Powerscope Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; NANOPARTICLE; FLUORESCEIN;

AEROSOL; AIR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CILIARY DISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DIFFUSION; GAS EXCHANGE; LIQUID; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZATION; SURFACE PROPERTY; SWINE; VITRECTOMY; VITREOUS BODY; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PILOT STUDY; RETINA;

AEROSOLS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; FLUORESCEIN; NANOPARTICLES; PILOT PROJECTS; RETINA; SUS SCROFA; VITRECTOMY;

EID: 38449112331     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0323     Document Type: Article

References (40)

1. Michels RG. Surgery of retinal detachment with proliferative vitreoretinopathy. Retina. 1984;4:63-83.
2. Ryan SJ. The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol. 1985;100:188-193.
3. Lewis H, Aaberg TM, Abrams GW. Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol. 1991;111:8-14.
4. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol. 1992;110: 780-792.
5. Hakin KN, Lavin MJ, Leaver PK. Primary vitrectomy for rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1993;231:344-346.
6. McCuen BW 2nd, Azen SP, Stern W, et al. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 3. Retina. 1993;13:279-284.
7. Sanabria Ruiz-Colmenares MR, Pastor Jimeno JC, Garrote Adrados JA, Telleria Orriols JJ, Yugueros Fernandez MI. Cytokine gene polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy: a preliminary study. Acta Ophthalmol Scand. 2006;84:309-313.
8. Johansson K, Malmsjo M, Ghosh F. Tailored vitrectomy and laser photocoagulation without scleral buckling for all primary rhegmatogenous retinal detachments. Br J Ophthalmol. 2006;90:1286-1291.
9. Heimann H, Zou X, Jandeck C, et al. Primary vitrectomy for rhegmatogenous retinal detachment: an analysis of 512 cases. Graefes Arch Clin Exp Ophthalmol. 2006;244:69-78.
10. Grigoropoulos VG, Benson S, Bunce C, Charteris DG. Functional outcome and prognostic factors in 304 eyes managed by retinectomy. Graefes Arch Clin Exp Ophthalmol. 2007;245:641-649.
11. Rodriguez de la Rua E, Pastor JC, Aragon J, et al. Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy. Curr Eye Res. 2005;30:147-153.
12. Chang PY, Yang CM, Yang CH, et al. Clinical characteristics and surgical outcomes of pediatric rhegmatogenous retinal detachment in Taiwan. Am J Ophthalmol. 2005;139:1067-1072.
13. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol. 2004;137:1105-1115.
14. Weinberg DV, Lyon AT, Greenwald MJ, Mets MB. Rhegmatogenous retinal detachments in children: risk factors and surgical outcomes. Ophthalmology. 2003;110:1708-1713.
15. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144.
16. Kim IK, Arroyo JG. Mechanisms in proliferative vitreoretinopathy. Ophthalmol Clin North Am. 2002;15:81-86.
17. Asaria RH, Kon CH, Bunce C, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology. 2001;108: 1184-1186.
18. Kon CH, Asaria RH, Occleston NL, Khaw PT, Aylward GW. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol. 2000;84:506-511.
19. El-Asrar AM, Al-Amro SA, Khan NM, Kangave D. Visual outcome and prognostic factors after vitrectomy for posterior segment foreign bodies. Eur J Ophthalmol. 2000;10:304-311.
20. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci. 1999;40:705-712.
21. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
22. Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998;17:77-98.
23. El-Asrar AM, Al-Amro SA, Khan NM, Kangave D. Retinal detachment after posterior segment intraocular foreign body injuries. Int Ophthalmol. 1998;22:369-375.
24. Nagasaki H, Shinagawa K. Risk factors for proliferative vitreoretinopathy. Curr Opin Ophthalmol. 1995;6:70-75.
25. Mangouritsas G, Rothbacher HH, Heidenkummer PH, Ulbig MW, Kampik A. Risk factors for surgical failures in rhegmatogenous retinal detachment [in German]. Klin Monatsbl Augenheilkd. 1995;206:20-28.
26. Bonnet M, Guenoun S. Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. Graefes Arch Clin Exp Ophthalmol. 1995;233: 789-791.
27. Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 1994;14:417-424.
28. Nagasaki H, Ideta H, Mochizuki M, Shibata A. A case-control study of risk factors for proliferative vitreoretinopathy in aphakia. Jpn J Ophthalmol. 1993;37:187-191.
29. Nagasaki H, Ideta H, Uemura A, Morita H, Ito K, Yonemoto J. Comparative study of clinical factors that predispose patients to proliferative vitreoretinopathy in aphakia. Retina. 1991;11:204-207.
30. Malbran E, Dodds RA, Hulsbus R, Charles DE, Buonsanti JL, Adrogue E. Retinal break type and proliferative vitreoretinopathy in nontraumatic retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1990;228:423-425.
31. Yoshino Y, Ideta H, Nagasaki H, Uemura A. Comparative study of clinical factors predisposing patients to proliferative vitreoretinopathy. Retina. 1989;9:97-100.
32. Cowley M, Conway BP, Campochiaro PA, Kaiser D, Gaskin H. Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol. 1989;107:1147-1151.
33. Bonnet M. The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Grade B: a determining risk factor. Graefes Arch Clin Exp Ophthalmol. 1988;226:201-205.
34. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179-1183.
35. Knudsen LL, Dissing T, Hansen MN, Nielsen-Kudsk F. Ocular fluorescein kinetics before and after vitrectomy on swine. Graefes Arch Clin Exp Ophthalmol. 2001;239:832-839.
36. Hinds W. Aerosol Technology: Properties, Behavior, and Measurements of Airborne Particles. New York: John Wiley & Sons; 1982.
37. Macha S, Mitra AK. Ocular pharmacokinetics in rabbits using a novel dual probe microdialysis technique. Exp Eye Res. 2001;72: 289-299.
38. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
39. Crank J. Mathematics of Diffusion. London: Oxford Press; 1981.
40. Crump J, Seinfeld J. Turbulent deposition and gravitational sedimentation of an aerosol in a vessel of arbitrary shape. J Aerosol Sci. 1981;12:405-415.